Skip to main content

MoonLake Immunotherapeutics

MLTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001821586

In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 6 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.

13F holders, Q1 2025

Institutional positions in MoonLake Immunotherapeutics as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
136
+21 vs. Q4 2024
Shares held
59.9M
−2.93M (−4.7%) vs. Q4 2024
Total value
$2.34B
−$1.06B (−31.2%) vs. Q4 2024
New holders
37
32 more added
Sold out
16
43 more reduced

1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting MLTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2025: 136 institutions
Q1 2021: 42 institutionsQ2 2021: 46 institutionsQ3 2021: 43 institutionsQ4 2021: 45 institutionsQ1 2022: 27 institutionsQ2 2022: 23 institutionsQ3 2022: 24 institutionsQ4 2022: 33 institutionsQ1 2023: 43 institutionsQ2 2023: 83 institutionsQ3 2023: 118 institutionsQ4 2023: 125 institutionsQ1 2024: 114 institutionsQ2 2024: 111 institutionsQ3 2024: 109 institutionsQ4 2024: 116 institutionsQ1 2025: 136 institutionsQ2 2025: 130 institutionsQ3 2025: 134 institutionsQ4 2025: 130 institutionsQ1 2026: 147 institutionsQ2 2026: 172 institutions
Value heldQ1 2025: $2.34B
Q1 2021: $108.9MQ2 2021: $115.8MQ3 2021: $111.1MQ4 2021: $112.8MQ1 2022: $123.4MQ2 2022: $190.1MQ3 2022: $291.4MQ4 2022: $396.4MQ1 2023: $843.2MQ2 2023: $2.86BQ3 2023: $3.21BQ4 2023: $3.53BQ1 2024: $2.99BQ2 2024: $2.67BQ3 2024: $3.14BQ4 2024: $3.43BQ1 2025: $2.34BQ2 2025: $2.77BQ3 2025: $269.7MQ4 2025: $742.9MQ1 2026: $1.17BQ2 2026: $1.43B
Institutions holding MLTX and their total value by quarter
QuarterHoldersValue
Q2 2026172$1.43B
Q1 2026147$1.17B
Q4 2025130$742.9M
Q3 2025134$269.7M
Q2 2025130$2.77B
Q1 2025136$2.34B
Q4 2024116$3.43B
Q3 2024109$3.14B
Q2 2024111$2.67B
Q1 2024114$2.99B
Q4 2023125$3.53B
Q3 2023118$3.21B
Q2 202383$2.86B
Q1 202343$843.2M
Q4 202233$396.4M
Q3 202224$291.4M
Q2 202223$190.1M
Q1 202227$123.4M
Q4 202145$112.8M
Q3 202143$111.1M
Q2 202146$115.8M
Q1 202142$108.9M

Institutions, Q1 2025

Shares, value and share of portfolio for each institution holding MoonLake Immunotherapeutics; share changes are against Q4 2024.

Institutions holding MLTX in Q1 2025
InstitutionSharesValue% of portfolioChange in sharesAction
First Turn Management, LLC179,196$7.00M1.41%+179,196New
Holocene Advisors, LP188,989$7.38M0.02%−1,396,178−88.1%Reduced
Franklin Resources Inc191,500$7.48M0.00%+191,500New
Integral Health Asset Management, LLC200,000$7.81M0.87%00.0%Unchanged
Vestal Point Capital, LP200,000$7.81M0.56%+200,000New
Ameriprise Financial Inc201,521$7.87M0.00%−2,852−1.4%Reduced
TD Asset Management Inc216,904$8.47M0.01%−44,730−17.1%Reduced
Victory Capital Management Inc258,150$10.1M0.01%+79,649+44.6%Added
5AM Venture Management, LLC282,313$11.0M4.17%00.0%Unchanged
BlackRock, Inc.286,209$11.2M0.00%−82,636−22.4%Reduced
Octagon Capital Advisors LP296,000$11.6M2.51%+296,000New
Woodline Partners LP296,148$11.6M0.08%+2,613+0.9%Added
MPM Oncology Impact Management LP316,049$12.3M2.12%+819+0.3%Added
Pictet Asset Management Holding SA322,114$12.6M0.01%−24,503−7.1%Reduced
Saturn V Capital Management LLC343,849$13.4M6.78%−2,262−0.7%Reduced
Millennium Management LLC344,320$13.5M0.01%+344,320New
Logos Global Management LP350,000$13.7M2.43%+350,000New
Voya Investment Management LLC392,924$15.4M0.02%−55,936−12.5%Reduced
Finepoint Capital LP435,785$17.0M2.87%−12,150−2.7%Reduced
Camber Capital Management LP441,000$17.2M1.08%00.0%Unchanged
Paradigm Biocapital Advisors LP627,423$24.5M1.13%−1,144,788−64.6%Reduced
Marshall Wace, LLP640,917$25.0M0.03%−604,382−48.5%Reduced
Fred Alger Management, LLC642,881$25.1M0.14%−30,892−4.6%Reduced
Hood River Capital Management LLC662,983$25.9M0.44%+13,393+2.1%Added
Nuveen, LLC673,343$26.3M0.01%+673,343New
Alliancebernstein L.P.966,090$37.7M0.01%−56,514−5.5%Reduced
Polar Capital Holdings Plc1,100,000$43.0M0.27%00.0%Unchanged
Federated Hermes, Inc.1,269,351$49.6M0.11%−10,701−0.8%Reduced
Goldman Sachs Group Inc1,292,608$50.5M0.01%−382,056−22.8%Reduced
Westfield Capital Management Co LP1,434,770$56.1M0.27%+123,151+9.4%Added
Citadel Advisors LLC1,478,635$57.8M0.06%−708,231−32.4%Reduced
Avoro Capital Advisors LLC2,770,100$108.2M1.69%00.0%Unchanged
Price T Rowe Associates Inc2,973,830$116.2M0.01%−369,813−11.1%Reduced
FMR LLC6,327,014$247.2M0.02%−14,377−0.2%Reduced
Cormorant Asset Management, LP8,494,151$331.9M25.13%00.0%Unchanged
BVF Inc19,751,284$771.7M31.45%00.0%Unchanged
EcoR1 Capital, LLC0$00.00%−332,522−100.0%Sold out
Adage Capital Partners GP, L.L.C.0$00.00%−155,000−100.0%Sold out
Alyeska Investment Group, L.P.0$00.00%−100,000−100.0%Sold out
Point72 Asset Management, L.P.0$00.00%−98,719−100.0%Sold out
Parkman Healthcare Partners LLC0$00.00%−54,294−100.0%Sold out
UBS Oconnor LLC0$00.00%−20,740−100.0%Sold out
Caption Management, LLC0$00.00%−12,371−100.0%Sold out
Cinctive Capital Management LP0$00.00%−10,576−100.0%Sold out
Y-Intercept (Hong Kong) Ltd0$00.00%−9,229−100.0%Sold out
Mariner, LLC0$00.00%−5,028−100.0%Sold out
PEAK6 LLC0$00.00%−5,000−100.0%Sold out
Parallax Volatility Advisers, L.P.0$00.00%−3,208−100.0%Sold out
Virtus ETF Advisers LLC0$00.00%−1,322−100.0%Sold out
Skopos Labs, Inc.0$00.00%−78−100.0%Sold out
National Bank of Canada0$00.00%−2−100.0%Sold out
IFP Advisors, Inc0$00.00%0Sold out
Nuveen Asset Management, LLC––––Not filed